Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after oral and intravenous administration of pentoxifylline to healthy adult horses

American Journal of Veterinary Research

Volumn 67, Issue 9, 2006, Pages 1621-1627

  Liska, Dana A ^a   Akucewich, Lisa H ^a   Marsella, Rosanna ^a   Maxwell, Lara K ^b   Barbara, Jonathan E ^c   Cole, Cynthia A ^a,d  

^a University of Florida College of Veterinary Medicine   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c Idexx Pharmaceuticals Inc ^*  (United States)

^d Idexx Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYHEXYLPENTOXIFYLLINE; DRUG METABOLITE; GENERIC DRUG; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FASCICULATION; FEMALE; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; MALE; NONHUMAN; SUSTAINED DRUG RELEASE; SWEAT GLAND DISEASE; TACHYCARDIA;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HORSES; INJECTIONS, INTRAVENOUS; MALE; PENTOXIFYLLINE; RANDOM ALLOCATION;

ANIMALIA; EQUIDAE;

EID: 33748744632     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.9.1621     Document Type: Article

References (36)

1. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology 1976;27:188-196.
2. Samlaska C, Winfield E. Pentoxifylline. J Am Acad Dermatol 1994;30:603-621.
3. Rosenthal LA, Taub DD, Moors MA, et al. Methylxanthine-induced inhibition of the antigen- and superantigen-specific activation of T and B lymphocytes. Immunopharmacology 1992;24:203-217.
4. Salyer JL, Bohnsack JF, Knape WA, et al. Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration. Am J Pathol 1990;136:831-841.
5. Berman B, Duncan MR. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J. Invest Dermatol 1989;92:605-610.
6. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
7. Haber P, Warner R, Seth D, et al. Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol 2003;18:1332-1334.
8. Parnetti L, Ciuffetti G, Mercuri M, et al. The role of haemorheological factors in the ageing brain: long term therapy with pentoxifylline ('Trental' 400) in elderly patients with initial mental deterioration. Pharmatherapeutica 1986;4:617-627.
9. Monteiro DT, Santamore WP, Nemir P. The influence of pentoxifylline on skin-flap survival. Plast Reconstr Surg 1986;77:277-281.
10. Dion MW, Jussey DH, Osborne JW. The effect of pentoxifylline on early and late radiation injury following fractionated irradiation in C3H mice. Int J Radiat Oncol Biol Phys 1989;17:101-107.
11. Wahba-Yahav AV. Chronic leukocytoclastic vasculitis associated with polycythemia vera: effective control with pentoxifylline. J Am Acad Dermatol 1992;26:1006-1007.
12. Marsella R, Kunkle GA, Lewis DT. Use of pentoxifylline in the treatment of allergic contact reactions to plants of the Commelinceae family in dogs. Vet Dermatol 1997;8:121-126.
13. Mueller R, Rosychuk R, Jonas L. A retrospective study regarding the treatment of lupoid onychodystrophy in 30 dogs and literature review. J Am Anim Hosp Assoc 2003;39:139-150.
14. Koutsarova N, Todorov P, Koutsarov G. Effects of pentoxifylline on motility and longevity of fresh and thawed dog spermatozoa. J Reprod Fertil Suppl 1997;51:117-121.
15. Barton MH, Moore JN. Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 1994;44:216-220.
16. Barton MH, Ferguson D, Davis PJ, et al. The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin Flα and ex vivo endotoxin-induced tumor necrosis factor activity in horses. J Vet Pharmacol Ther 1997;20:487-492.
17. Rames A, Poirier JM, LeCoz F, et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 1990;47:354-359.
18. Beermann B, Ings R, Mansby J, et al. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985;37:25-28.
19. Marsella R, Nicklin C, Munson JW, et al. Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am J Vet Res 2000;61:631-637.
20. Rees CA, Boothe DM, Boeckh A, et al. Dosing regimen and hematologic effects of pentoxifylline and its active metabolites in normal dogs. Vet Ther 2003;4:188-196.
21. Crisman MV, Wilcke JR, Correll LS, et al. Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. J Vet Pharmacol Ther 1993;16:23-31.
22. Ingle-Fehr JE, Baxter GM. The effect of oral isoxsuprine and pentoxifylline on digital and laminar blood flow in healthy horses. Vet Surg 1999;28:154-160.
23. Leguillette R, Desevaux C, Lavoie JP. Effects of pentoxifylline on pulmonary function and results of cytologic examination of bronchoalveolar lavage fluid in horses with recurrent airway obstruction. Am J Vet Res 2002;63:459-463.
24. Luke DR, Rocci ML Jr. Determination of pentoxifylline and a major metabolite, 3,7-dimethyl-1-(5-hydroxyhexyl)xanthine, by high-performance liquid chromatography. J Chromatogr 1986;374:191-195.
25. Gibaldi M, Perrier D. Multiple dosing. In: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982;113-144.
26. Lam F, Hung C, Perrier D. Estimation of variance for harmonic mean half-lives. J Pharm. Sci 1985;74:229-231.
27. O'Neil MJ, Smith A, Heckelman PE, et al. Monographs. In: O'Neil MJ, Smith A, Heckelman PE, et al, eds. The Merck index. 13th ed. Whitehouse Station, NJ: Merck & Co Inc, 2001; 1280.
28. Srinivasu P, Rao BR, Rao YM, et al. Circadian variations in the pharmacokinetics of pentoxifylline in man. J Pharm Pharmacol 1998;50:71-74.
29. Denlinger CL, Stryker KK, Slusher LB, et al. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine. Clin Pharmacol Ther 1987;41:522-530.
30. Hinze HJ, Bedessem G, Soder A. Structure of the excretion products of 3,7-dimethyl-1-(5-oso-hemyl)-xanthine (BL 191) in man. Arzneimittelforschung 1972;22:1144-1151.
31. Kwong EC, Chen FC, Young LM. Urinary excretion of pentoxifylline and its metabolites by standardbred mares. Can J Vet Res 1989;53:147-153.
32. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 1984;35:407-417.
33. Moffat AC, Jackson JV, Moss MS, et al. Analytical and toxicological data. In: Moffat AC, Jackson JV, Moss MS, eds. Clarke's isolation and identification of drugs. 2nd ed. London: The Pharmacological Press, 1986;838.
34. Suarez-Penaranda JM, Rico-Boquete R, Lopez-Rivadulla M, et al. A fatal case of suicidal pentoxifylline intoxication. Int J Legal Med 1998;111:151-153.
35. Manohar M, Goetz TE, Rothenbaum P, et al. Intravenous pentoxifylline does not enhance the pulmonary haemodynamic efficacy of frusemide in strenuously exercising Thoroughbred horses. Equine Vet J 2001;33:354-359.
36. Barton MH, Moore JN, Norton N. Effects of pentoxilylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 1997;58:1300-1307.